Metabolic (FDG–PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure

Manus, Michael P. Mac; Hicks, Rodney J.; Matthews, Jane P.; Wirth, Andrew; Rischin, Danny; Ball, David

doi:10.1016/j.lungcan.2004.11.024

Cited by 149 publications

(107 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a prospective study, PET and CT assessments performed at a median of 70 days after RT, were concordant in only 40% of cases [81]. PET response was the best predictor of survival, was strongly-correlated with patterns of failure [82] and was not confounded by normal tissue reactions [83] .…”

Section: Tumor Movementmentioning

confidence: 99%

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

MacManus

Nestle

Rosenzweig

et al. 2009

Radiotherapy and Oncology

333

197

View full text Add to dashboard Cite

show abstract

Section: Tumor Movementmentioning

confidence: 99%

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

MacManus

Nestle

Rosenzweig

et al. 2009

Radiotherapy and Oncology

333

197

View full text Add to dashboard Cite

show abstract

“…18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has been revealed to be a useful technique for tumor staging through its ability to detect of tumor extension or metastasis (11)(12)(13)(14). In several types of tumor, FDG-PET has been demonstrated to predict survival and treatment response (15)(16)(17). A meta-analysis of 13 studies on NSCLC treated with surgery revealed that a high FDG-PET standardized uptake value (SUV) of the primary tumor was a prognostic factor for unfavorable survival (18).…”

Section: Introductionmentioning

confidence: 99%

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

et al. 2017

View full text Add to dashboard Cite

Abstract. The present study (University Hospital Medical Information Network study no. UMIN000003797) aimed to evaluate whether the maximum standardized uptake value (SUV max ) of pretreatment 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET) is prognostic factor for stage I non-small cell lung cancer (NSCLC) treated with carbon ion radiotherapy (C-ion RT). Patients treated between June 2010 and June 2013 at Gunma University Heavy Ion Medical Center (Maebashi, Japan) on a prospective protocol were included in the present study. Patients with T1a-b and T2a NSCLC were treated with C-ion RT at a dose of 52.8 Gy [relative biological effectiveness (RBE)] and 60.0 Gy (RBE), respectively, in four fractions. Prior to treatment, all patients underwent FDG-PET, in which the SUV max of primary tumors was evaluated. Local control, progression-free survival (PFS), and overall survival (OS) were calculated. A total of 45 patients were analyzed and the median follow-up period was 28.9 months. The 2-year local control, PFS and OS rates for all patients were 93, 78 and 89%, respectively. The mean SUV max of primary tumors was 5.5, and patients were divided into higher (≥5.5) and lower (<5.5) SUV max groups. The 2-year PFS rates were 61 and 89% for the higher and lower SUV max groups, respectively (P=0.01), and the 2-year OS rates for the higher and lower SUV max groups were 76 and 96%, respectively (P=0.01). The higher SUV max group exhibited a significantly worse PFS and OS compared with the lower SUV max group; however, the SUV max was not associated with the local control rate. In total, 2 patients (4%) experienced grade 2 or 3 radiation pneumonitis, with their symptoms improved through conservative treatment. No patients experienced any grade 4 or 5 toxicities. The results of the present study indicate that pretreatment SUV max is a prognostic indicator for outcomes in patients with stage I NSCLC treated with C-ion RT.

show abstract

“…Traditional therapy methods of spinal metastases include radiotherapy, chemotherapy, isotopic therapy, bisphosphonate therapy, pain relief treatment and the palliative surgical treatment (16). Choice of treatment depends on histological type of the primary tumors, neurological function prior to treatment, number of the involved vertebrae, vertebral level, the location of osteolytic lesions within the vertebral body, intraspinal degree of diffusion, the patient's general condition and the severity of pain.…”

Section: Traditional Methods For Treating Cancer Metastasis Of Posterimentioning

confidence: 99%

Advances in the clinical research of the minimally invasive treatment for the posterior edge of vertebral-body defects by spinal metastases

et al. 2015

View full text Add to dashboard Cite

Abstract.Spinal metastasis is one of the commonly observed complications in the advanced stages of cancer patients, and is a serious threat to human life and health. Malignant tumor invasion usually leads to defects in the posterior margins of the vertebral body, which caused significant cancer pains to patients and increased the risk of surgery. Currently, minimally invasive treatments of vertebral defects caused by spinal metastases include percutaneous vertebroplasty (PVP) combined with radiofrequency ablation and PVP combined with 125 I seed implantation. These minimally invasive techniques have particular superiority to control pain in patients with spinal metastases, improve nerve function, reduce the incidence of fractures and surgical risk, and improve the quality of life. The present study reviewed the progress in clinical research on vertebral defects caused by spinal metastases, and the mechanisms and minimally invasive treatment.

show abstract

Metabolic (FDG–PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure

Cited by 149 publications

References 21 publications

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

Maximum standardized uptake value on FDG-PET predicts survival in stage I non-small cell lung cancer following carbon ion radiotherapy

Advances in the clinical research of the minimally invasive treatment for the posterior edge of vertebral-body defects by spinal metastases

Contact Info

Product

Resources

About